The phase III trial of 'Covishield' vaccine will begin at Sassoon hospital from next week, said Dr Muralidhar Tambe, Dean of Sassoon General Hospital
The vaccine maker earlier shortlisted 17 sites in India for the Phase II clinical trial of COVID-19 vaccine
There will be 4,000-5,000 participants in the phase III trial of Oxford COVID-19 vaccine in India.
The Serum Institute of India is all set to begin the final stage of the clinical trial of University of Oxford and AstraZeneca Plc.’s experimental vaccine, starting from next week. The late-stage trial will take place at the Sassoon General Hospital in Pune, according to news agency PTI.
"The phase III trial of Covishield vaccine will begin at Sassoon hospital from next week. It is likely to start on Monday." Dr Muralidhar Tambe, Dean of Sassoon General Hospital, told the news agency.
In the third phase of clinical trial, around 150-200 volunteers will administer a dose of Covishield. "Some volunteers have already come forward for the trial," Tamble further added. The Sassoon General Hospital in Pune has started enrolling volunteers from Saturday. "Those who are willing to volunteer for the vaccination should contact the hospital," Tamble encouraged.
The phase II trial of Covishield was conducted at Bharti Vidyapeeth Medical College and King Edward Memorial (KEM) Hospital in Pune.
Pune-based drug maker signed a deal with British-Swedish company AstraZeneca to manufacture COVID-19 vaccine candidate, developed by the University of Oxford. The vaccine maker earlier shortlisted 17 sites in India for the Phase II clinical trial of COVID-19 vaccine. At least 1,600 candidates aged between 18 to 55, participated in the Phase II clinical trial.
On September 10, the drug maker had paused the clinical trials of the Oxford COVID-19 vaccine candidate in India in the wake of AstraZeneca suspending the clinical trials in other countries. Drugs Controller General of India (DCGI) Dr VG Somani on September 15 granted permission to Serum Institute of India to resume trial, while revoking its earlier order of suspending any new recruitment for phase II and III trial.
COVID-19 vaccine candidate developed by the Jenner Institute, a part of the Nuffield Department of Medicine at the University of Oxford, showed a positive result in its initial trial. According to a report published in the British medical journal, The Lancet, the COVID-19 vaccine produced a dual immune response in people aged 18 to 55.
The University of Oxford's possible COVID-19 vaccine could be rolled out by the end of the year but there is no certainty, the lead developer of the vaccine. "The end of the year target for getting vaccine roll-out, it's a possibility but there's absolutely no certainty about that because we need three things to happen," Sarah Gilbert earlier told.
Serum Institute of India will begin the trial of another COVID-19 vaccine candidate developed by Novavax in next month. US drug developer Novavax Inc said it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Indian drug maker. As part of the expanded agreement, Serum Institute will also manufacture the antigen component of the vaccine.
Source - liveMint
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.